This article was originally published in The Gray Sheet
CMS national coverage decision will catalyze home-use of blood microcoagulation testing system in $100 mil. market, cardiovascular firm claims June 3. Manufactured and marketed by Thoratec's International Technidyne Corporation (ITC) division, the ProTime measures prothrombin time in patients with a mechanical heart valve and who are taking blood-thinning drugs. Medicare reimbursement is currently available only for testing done at a physician's office or lab. New coverage for the equipment is expected to become effective on July 1, 2002...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.